Moderna posts Q3 revenue of $1.31 billion, lowers full-year R&D spending outlook
Moderna disclosed third-quarter revenue of $1.31 billion against an estimate of $888.1 million, with earnings of 38 cents per share versus an estimated loss of $1.09. The company lowered its full-year research and development expense outlook to about $2.7 billion from about $2.9 billion. It also projected full-year capital expenditure of $200 million, compared with its previous range of $200 million to $300 million.